Clinical trials: Non-Alcoholic SteatoHepatitis (NASH)
Non Alcoholic Steatohepatitis
The Effect of Synbiotics Supplement on Lipid Profile, Liver Enzymes, Inflammatory Factors and Hepatic Fibrosis in Lean and Normal Weight Patients With Nonalcoholic Fatty Liver
Introduction: Currently, Nonalcoholic Fatty Liver Disease (NAFLD) is the most common liver disease in the world. The only approved treatment for it is lifestyle modification and weight loss; however, there is no evidence for…
- Trial name
- NCT02530138
- Testing
- synbiotic
- Where
- Iran
- Volunteers
- 42 people
- Sponsor
- National Nutrition and Food Technology Institute
Non-alcoholic Steatohepatitis, Fatty Liver
An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis
To evaluate the safety and tolerability of Nitazoxanide (NTZ) 500mg Twice Daily (BID) after 24 weeks of treatment in patients with NASH induced Stage 2 or Stage 3 fibrosis
- Conditions
- Non-alcoholic Steatohepatitis, Fatty Liver, Fibrosis, Liver, Compensated Cirrhosis
- Trial name
- NCT03656068
- Testing
- Nitazoxanide 500mg BID
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Pinnacle Clinical Research, PLLC
Non-Alcoholic Fatty Liver Disease
A Clinical Trial to Evaluate the Efficacy and Safety of MXP22 on Liver Health
A randomized, double blind, placebo controlled clinical trial to evaluate the efficacy and safety of MXP22 on liver health
- Trial name
- NCT05808049
- Testing
- MXP22 (Probiotic and antioxidant capsule)
- Where
- 2 sites in India
- Volunteers
- 60 people
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Sleep Apnea, Obstructive, Fatty Liver
Prevalence of Non-alcoholic Fatty Liver Disease Among Non-obese Obstructive Sleep Apnea by Using Transient Elastography
Obstructive sleep apnea (OSA) and non-alcoholic fatty liver disease (NAFLD) are both common diseases related to metabolic diseases with potential cardiovascular consequences and liver complications respectively.
- Trial name
- NCT05351515
- Where
- Hong Kong
- Volunteers
- 861 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Metabolic Associated Fatty Liver Disease
MAFLD-simplified Definition as an Optimized Risk Stratification Tool for Predicting Metabolic Outcomes
Recently, a consensus was proposed by an international expert panel for the terminology changed from NAFLD to Metabolic associated fatty liver disease (MAFLD). The comprehensive criteria shift to a "positive" diagnosis.
- Trial name
- NCT04761900
- Testing
- the differences of MAFLD and MAFLD-simplified definitions were compared in predicting metabolic diseases
- Volunteers
- 3,372 people
- Sponsor
- Ningbo No. 1 Hospital
Hepatic Steatosis
Effects of a Low Glycemic Load Diet on Fatty Liver in Children
There has been a recent increase in incidence of obesity and its associated morbidities, including T2 DM, hypertension and hepatic steatosis.
- Trial name
- DELIVER (NCT00480922)
- Testing
- Low glycemic load diet, Low fat diet
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Boston Children's Hospital
Nonalcoholic Fatty Liver Disease, Light-to-moderate Alcohol Consumption
Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver Disease
This study explored the cross-sectional and prospective associations between light-to-moderate alcohol consumption (LMAC) and risk of type 2 diabetes mellitus (T2DM) in individuals with nonalcoholic fatty liver disease (NAFLD).
- Conditions
- Nonalcoholic Fatty Liver Disease, Light-to-moderate Alcohol Consumption, Type2 Diabetes Mellitus
- Trial name
- NCT03847116
- Where
- China
- Volunteers
- 14,014 people, healthy volunteers welcome
- Sponsor
- Ningbo No. 1 Hospital
NAFLD
Human Liver ORganoids as a Model to Study the Development of Non-Alcoholic SteatOhepatitis (NASH)
The primary objective of the study is to generate and characterize three-dimensional models, called "assembloids", composed of the main liver cell populations (in particular from the co-culture of organoids with stellate cells…
- Trial name
- REASON (NCT06856252)
- Testing
- Liver resection to isolate cells
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Fatty Liver
Cilostazol in the Treatment of Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries (1).
- Trial name
- NCT07238985
- Testing
- Standard therapy, Cilostazol
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Tanta University
Obesity, Fatty Liver
Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
To evaluate the impact of a Low Carbohydrate Ketogenic Diet (LCKD) weight loss program and compare to the standard of care program established for patients with Non-Alcoholic Fatty Liver Disease (NAFLD) on: (1) Liver fat and…
- Conditions
- Obesity, Fatty Liver, Ketogenic Dieting
- Trial name
- NCT03141008
- Testing
- Fibroscan changes with different diets
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Fatty Liver
A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease
Non Alcoholic Fatty Liver Disease (NAFLD) is considered as the component of metabolic syndrome. The prevalence of the same has been increasing rapidly in India, along with an increase in the prevalence of diabetes and obesity.
- Trial name
- GLAZED (NCT02265276)
- Testing
- Saroglitazar, Pioglitazone
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Command Hospital, India
Non-Alcoholic Fatty Liver Disease, Bariatric Surgery
Liver Fat Content and Bariatric Surgery
On the basis of previous research, this subject intends to evaluate the liver improvement of patients with liver disease after weight loss by MRI, and quantify it by extracting features, so as to provide a new method to judge the…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Bariatric Surgery, Magnetic Resonance Imaging
- Trial name
- NCT06064240
- Testing
- We do not have any intervention type
- Where
- China
- Volunteers
- 50 people
- Sponsor
- yu li，MD
Non-Alcoholic Fatty Liver Disease, Obesity
Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Nonalcoholic fatty liver disease (NAFLD) is common in individuals with obesity and is a significant threat to public health, because it can lead to impaired liver function and liver failure.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Obesity, Abdominal, Liver Fat
- Trial name
- NCT03375788
- Testing
- Tesamorelin
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Massachusetts General Hospital
Non-alcoholic Fatty Liver Disease
Prospective, Cross-sectional and Multicenter Study, Evaluating the Diagnosis Accuracy of the Controlled Attenuation Parameter(CAP) Measured by FibroScan® (Either With M+ or XL+ Probe) in Patient With Non-Alcoholic Fatty Liver Disease Using Liver Biopsy as Reference.
The non-alcoholic fatty liver disease (NAFLD) represents the most common cause of liver disease in the western world. It can progress from steatosis to non-alcoholic steatohepatitis (NASH), and then onto cirrhosis where there is…
- Trial name
- NCT01985009
- Testing
- FibroScan® examination.
- Where
- 7 sites in United Kingdom
- Volunteers
- 450 people
- Sponsor
- Echosens
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease
Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)
This project, "A double-blind placebo-controlled randomized clinical trial assessing the efficacy of metformin for hepatic fat in adolescents and young adults with polycystic ovary syndrome", proposes exploring the use of novel…
- Conditions
- Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
- Trial name
- NCT02500147
- Testing
- Metformin
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Fatty Liver
Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease
The purpose of this study is to evaluate the effect of GWP42003 on liver triglyceride (liver fat) in participants with fatty liver disease (FLD).
- Trial name
- NCT01284634
- Testing
- GWP42003 200 mg/day Dose, GWP42003 400 mg/day Dose, GWP42003 800 mg/day Dose
- Where
- 3 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- GW Research Ltd
Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)
Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant
The primary objective of this study is to evaluate the pharmacokinetics (PK) of miricorilant in the presence and absence of the strong cytochrome P450 [(CYP) 2C19] inhibitor, fluvoxamine, in healthy participants.
- Trial name
- NCT05712265
- Testing
- Miricorilant, Fluvoxamine
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
NAFLD, Nonalcoholic Fatty Liver
Accurate Point of Care Liver Disease Diagnostics
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. The investigators are testing a new technology to evaluate the liver (LiverScope®), and they will compare it to…
- Trial name
- NCT05986916
- Testing
- Liverscope® exam, MR exam, FibroScan® exam (optional)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
NAFLD, Web
Web-based Interventions on Nonalcoholic Fatty Liver Disease (NAFLD) in Obese Children
The web-based continuity of care intervention model to provide comprehensive nursing interventions for obese children with NAFLD, always tracking their performance status, enabling them to grasp the knowledge of healthy weight…
- Conditions
- NAFLD, Web, Childhood Obesity
- Trial name
- NCT05527938
- Testing
- web-based intervention
- Where
- China
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Shaoxing Maternity and Child Health Care Hospital
Non-alcoholic Fatty Liver Disease
Single Dose of PF-06835919 Escalation Study in Healthy Adult Subjects
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of a single dose of PF-06835919 in healthy adult subjects.
- Trial name
- NCT02974374
- Testing
- PF-06835919
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer